Blackstone Invests $750 Million in Moderna for Flu Vaccine Development

The investment aims to support Moderna's diversification efforts and advance its flu vaccine program, leveraging mRNA technology.

Blackstone Life Sciences invests up to $750 million in Moderna for flu vaccine development, with potential royalties and milestone payments.
Moderna's stock rises following the announcement, reflecting investor confidence in the company's expanding vaccine portfolio.
The investment supports Moderna's efforts to diversify beyond COVID-19 vaccines, utilizing mRNA technology for flu, norovirus, and other diseases.
Moderna has multiple vaccines in Phase 3 trials, including for norovirus, Epstein-Barr virus, and Varicella-Zoster virus, aiming to address significant unmet medical needs.
The collaboration with Blackstone underscores Moderna's strategy to partner with leading life science companies to advance vaccine development.